Eficacia y seguridad de los aminobifosfonatos en el tratamiento de la osteoporosis postmenopáusica
- F.R. Pérez López
- Javier Ferrer Barriendos
- Agustín Gómez de la Cámara
- Santiago Palacios Gil-Antuñano
- Francisco José Quereda Seguí
- José Manuel Quesada Gómez
- I. Rodríguez Arboleya
- Marta Esther Vázquez Fernández
ISSN: 1132-8460
Year of publication: 2004
Volume: 13
Issue: 1
Pages: 13-20
Type: Article
More publications in: Revista Española de Enfermedades Metabólicas Oseas
Abstract
Aminobisphosphonates are a drug family widely used in the treatment of postmenopausal osteoporosis, a disease with high incidence and prevalence basically due to aging of the population. In this review, the most important findings in regards to efficacy and safety of both preclinical and clinical studies with the most studied aminobisphosphonates in postmenopausal osteoporosis are gathered, with special focus on alendronate as it is used most in our country. Aminated bisphosphonates are effective in the prevention of vertebral as well as non-vertebral osteoporotic fractures, reaching the maximum levels of evidence among the presently approved drugs for postmenopausal osteoporosis treatment. The positive actions on fractures are maintained during the entire treatment in the very long term (data available for up to 10 years with alendronate and 7 years with risedronate). These findings, added to the results of the histomorphometric and microradiographic studies of bone biopsies in treated animals and humans, indicate that it is very unlikely that the continued treatment with aminated bisphosphonates for long periods has harmful effects on bone quality. As a whole, aminobisphosphonates are one of the most useful therapeutical tools presently available for the treatment of postmenopausal osteoporosis.